The Effect of Spironolactone on Acute Kidney Injury in Patients Undergoing Coronary Angiography

Alhasan Mujtaba Abdul-Wahid490 enrolled

Overview

an interventional study to measure the possible effects of spironolactone ( an aldosterone antagonist) on the incidence of acute kidney injury after coronary angiography

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

QUADRUPLE

Enrollment

490

Conditions

Acute Kidney Injury IHD Contrast-induced Nephropathy

Interventions

SpironolactoneDRUG

each patient will receive 200 mg of spironolactone as per his/her angiography premedications

Placebo Oral TabletDRUG

Each patient will receive a placebo tablet as per his/her angiography premedications

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients admitted to angiography unit * over 18 * informed consent Exclusion Criteria: * acute renal failure before 7 days * spironolactone contraindications * hyperkalemia (S.K. \>5.5 mEq/L) * documented tumor * actively taking NSAIDs, Ciclosporin, Cisplatin,

Locations (1)

Al-Sader Teaching Hospital

Basra, Iraq

Outcomes

Primary Outcomes

Acute kidney injury by K-DIGO guidelines

an absolute elevation of serum creatinine of 0.5mg/dl or 25% above baseline

Time frame: 48-72 hrs

Secondary Outcomes

acute kidney injury by NGAL

assessment of serum NGAL at admission and after 6 hrs to detect possible AKI in selected patients

Time frame: 6 hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.